MX362111B - Un metodo para mejorar la funcion hepatica. - Google Patents

Un metodo para mejorar la funcion hepatica.

Info

Publication number
MX362111B
MX362111B MX2014014317A MX2014014317A MX362111B MX 362111 B MX362111 B MX 362111B MX 2014014317 A MX2014014317 A MX 2014014317A MX 2014014317 A MX2014014317 A MX 2014014317A MX 362111 B MX362111 B MX 362111B
Authority
MX
Mexico
Prior art keywords
liver function
improving liver
improving
methazolamide
therapy
Prior art date
Application number
MX2014014317A
Other languages
English (en)
Other versions
MX2014014317A (es
Inventor
Walder Ken
Krippner Guy
Nicholson Geoff
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of MX2014014317A publication Critical patent/MX2014014317A/es
Publication of MX362111B publication Critical patent/MX362111B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente descripción se refiere generalmente al uso de metazolamida en terapia. La descripción se refiere además al tratamiento de disfunción hepática, o mejora de la función hepática, en un paciente.
MX2014014317A 2012-05-24 2013-03-15 Un metodo para mejorar la funcion hepatica. MX362111B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US201261666574P 2012-06-29 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Publications (2)

Publication Number Publication Date
MX2014014317A MX2014014317A (es) 2015-08-10
MX362111B true MX362111B (es) 2019-01-07

Family

ID=49622927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014317A MX362111B (es) 2012-05-24 2013-03-15 Un metodo para mejorar la funcion hepatica.

Country Status (15)

Country Link
US (2) US20150150855A1 (es)
EP (1) EP2854807A4 (es)
JP (2) JP6360826B2 (es)
KR (1) KR20150023405A (es)
CN (2) CN104487073A (es)
BR (1) BR112014029308A2 (es)
CA (1) CA2874513A1 (es)
CO (1) CO7160082A2 (es)
HK (1) HK1209051A1 (es)
MX (1) MX362111B (es)
NZ (2) NZ702645A (es)
RU (1) RU2653478C2 (es)
SG (2) SG11201407787VA (es)
WO (1) WO2013173859A1 (es)
ZA (1) ZA201408704B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
HK1209041A1 (en) * 2012-05-24 2016-03-24 Verva Pharmaceuticals Ltd A method of weight reduction
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
PL2106260T3 (pl) * 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
HK1209041A1 (en) * 2012-05-24 2016-03-24 Verva Pharmaceuticals Ltd A method of weight reduction

Also Published As

Publication number Publication date
CO7160082A2 (es) 2015-01-15
KR20150023405A (ko) 2015-03-05
RU2014152196A (ru) 2016-07-20
CN104487073A (zh) 2015-04-01
HK1209051A1 (en) 2016-03-24
JP6360826B2 (ja) 2018-07-18
WO2013173859A1 (en) 2013-11-28
NZ702645A (en) 2016-08-26
US20150150855A1 (en) 2015-06-04
RU2653478C2 (ru) 2018-05-08
MX2014014317A (es) 2015-08-10
SG10201705388XA (en) 2017-07-28
BR112014029308A2 (pt) 2017-06-27
SG11201407787VA (en) 2014-12-30
JP6412241B2 (ja) 2018-10-24
ZA201408704B (en) 2018-07-25
CA2874513A1 (en) 2013-11-28
NZ723206A (en) 2018-02-23
JP2018090589A (ja) 2018-06-14
CN109498623A (zh) 2019-03-22
US20180333399A1 (en) 2018-11-22
EP2854807A4 (en) 2016-03-16
JP2015517534A (ja) 2015-06-22
EP2854807A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
AU2011328009A8 (en) Compounds and methods for treating pain
PH12015502042B1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
EA201490559A1 (ru) Композиция для лечения свища
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015501088A1 (en) Dimeric compounds
NZ628433A (en) Chitosan-derived compositions
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX364220B (es) Metodos de tratamientos de fibrosis.
SG10201804034QA (en) Methods for treating hypotension
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
MX362111B (es) Un metodo para mejorar la funcion hepatica.
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
IN2015KN00676A (es)
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Legal Events

Date Code Title Description
FG Grant or registration